Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Ensem Therapeutics
Eli Lilly and Company
Eli Lilly and Company
Inhibrx Biosciences, Inc
Eli Lilly and Company
Turning Point Therapeutics, Inc.
Marengo Therapeutics, Inc.
Hoffmann-La Roche
Atara Biotherapeutics